Investors in Health

The fund is primarily supported by institutional investors, including public bank Bpifrance and insurance companies MACSF, Sogécap, and Crédit Agricole Assurances. Varsity has collaborated with asset management firm Elevation Capital Partners to establish a feeder fund that will contribute to the VC's second closing.

Founded by two childhood friends, Régis Micheli and Benjamin Vedrenne-Cloquet, who turned entrepreneurs and investors, JuneX Capital Partners is a founder-centric investment firm integrating a “Founders Office” and an evergreen investment fund. JuneX’s investment strategy focuses on backing entrepreneurs in the areas of human capital (training, education, employment, health, nutrition, and environment) and investment management (venture capital, private equity, and asset management). Working closely with entrepreneurs, JuneX provides a range of patient and agile capital solutions tailored to founders’ needs. Moreover, in specific situations, it may offer operational and advisory support as an operating or sparring partner. JuneX invests mostly, but not exclusively, in Europe and operates out of the UK and France.

The Merantix AI Fund builds and invests in category-defining early-stage AI-native companies, always seeking the largest exponential lever through AI as a general-purpose technology. We strongly believe in and focus on vertically integrated business models, data flywheel effects, multidisciplinary founding teams, societal impact, and leveraging the European industry sovereignty.

We complement our own research and development capabilities with those of external researchers, startups and other partners to bring innovative products and services to market more quickly. As part of our open innovation approach, we also invest into startup companies and organizations through venture capital (VC). We have a long track record of leveraging VC investing to help us to stay on top of the latest food industry trends. Today, we focus on three investment pillars - health science, innovation and sustainability - to drive new business and support our path to Net Zero, with businesses and technologies that can be deployed across our value chain. Through VC funding, we provide catalytic capital to support pioneering ideas on their launch and growth journey. Our investment strategy is predominantly based on a fund of funds approach, where we invest in VC funds with a proven track record and industry expertise.

The healthtech arm of IPQ Capital, the Family Office of Fryland Møller Pathiraja family. We invest in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Beringea is a transatlantic venture capital investor that seeks to create lasting success for rapidly scaling entrepreneurial companies. We provide patient and intelligent capital and a global footprint to back entrepreneurs throughout their journey. For U.K. and European entrepreneurs: We'll typically make an initial investment between £1-10 million into companies turning over approximately £1 million or more. We tend to lead Series A or Series B rounds, with further funding available for follow-on investments.

Convertible Tech Notes I seeks to consolidate a new investment category within the asset manager after years of experience in convertible notes through other vehicles of the firm, in which €200M+ has been invested in more than 100 operations through this product. It will invest between €1.5M to €3.5M in 15-20 technology companies both in Spain and the rest of Europe, being agnostic in terms of sector, but with a clear focus on technological models with traction and recurring character in the areas of Health, Cybersecurity, Financial Control, Telecommunications, Data & Analytics, Industrial, Artificial Intelligence or similar. The investment strategy is materialized through convertible instruments for companies in the expansion phase, with signs of maturity and high growth capacity.

For 20 years, Adara Ventures has partnered with exceptional early-stage European founders targeting global B2B markets. ‍ The fund has a target size of €120 million to invest in cutting-edge technologies and solutions that accelerate the energy transition in Europe. After 20 years of a successful track record in deep tech investments across Europe, Adara is naturally expanding to tackle one of the European economy's most complex challenges: balancing the Energy Trilemma to create an energy system that is reliable, affordable, and sustainable.

Digital healthcare, innovations and environmental health.

*Community based training program and team traing program focusing priorities on protection is better than cure. Digital health, healthcare and laboratory research programs. *Environmental health Protection. *Innovations and AI.

GrayBella Capital (GBC) is a pan-European VC Fund based in London. GBC specializes in high-growth deep-tech and health-tech companies across the UK and Europe. We invest at Series A and beyond, backing transformative innovations in AI, material science, robotics, medical devices, digital health, AI, diagnostics, and healthcare platforms. We only invest in B2B. We do not invest in consumer tech or therapeutics. We typically serve as a Lead or co-Lead.

Bringing your AI solutions to market! Turning an idea into an MVP is not the main challenge for most tech founders. Bringing their solution to market is. We bridge the gap between tech founders and their market potential. According to the ancient art of stoic philosophy, it’s crucial to stay indifferent to external events and always keep your mind on the fundamentals instead of hypes. With Indifferent Ventures we do just that, because “what stands in the way, becomes the way”. We support projects that are not floating on the hypes around the phenomenon of Tech/AI, but on the actual implementation and adoption of its vast potential into European society and the European labour force. ​